Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05609370 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
A Phase 1 study of Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, sponsored by BeiGene.
- Active
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT05609370 is a Phase 1 study of Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 113 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT05609370, a Phase 1 study of Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Tislelizumab
- DRUG 5-Fluorouracil
- DRUG LBL-007
- DRUG Bevacizumab or Bevacizumab biosimilar
Study Locations (20)
California
- Toi Clinical Research - Cerritos
- Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- UCLA - Los Angeles
- Hoag Memorial Presbyterian - Newport
- Kaiser Permanente Northern California - Vallejo
Kentucky
- Baptist Health Lexington - Lexington
- University of Kentucky Markey Cancer Center - Lexington
- Norton Cancer Institute - Louisville
Louisiana
- Pontchartrain Cancer Center - Covington
- Ochsner Clinic Foundation - New Orleans
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
- Cancer Care Specialists - Reno
Alaska
- Alaska Oncology and Hematology, Llc - Anchorage
Arizona
- Banner Md Anderson Cancer Center - Gilbert
Florida
- Baptist Md Anderson Cancer Center - Jacksonville
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2023-01-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05609370
The ClinicalTrials.gov registry entry for NCT05609370 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT05609370 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Kentucky, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05609370 about?
NCT05609370 is a clinical study titled "A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer". This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colo...
What is the current status of trial NCT05609370?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2023-01-29. Estimated completion is 2026-12-31.
What conditions does trial NCT05609370 study?
This clinical trial studies the following conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer.
What interventions are being tested in trial NCT05609370?
The interventions under investigation include: Capecitabine (DRUG), Tislelizumab (DRUG), 5-Fluorouracil (DRUG), LBL-007 (DRUG), Bevacizumab or Bevacizumab biosimilar (DRUG).
Who is sponsoring clinical trial NCT05609370?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05609370 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.